FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Allergy topics
Autoimmune
Prophylactic
Ophthalmic
Autoimmune Disorder
Immune Disorder
Dermatitis
Staurosporin
Aspergillosis
Angioedema
Allergic Rhinitis
Food Allergy
Therapeutical
Bronchopulmonary
Staurosporine
Sudden Infant Death

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Allergy patents



      
           
This page is updated frequently with new Allergy-related patent applications. Subscribe to the Allergy RSS feed to automatically get the update: related Allergy RSS feeds. RSS updates for this page: Allergy RSS RSS


Nanoparticles for treatment of allergy

Allertein Therapeutics

Nanoparticles for treatment of allergy

Nanoparticles for treatment of allergy

Cmg Pharmaceutical

Novel pyridopyrimidine derivatives and use thereof

Date/App# patent app List of recent Allergy-related patents
07/02/15
20150183848
 Treatment of lge-mediated disease patent thumbnailnew patent Treatment of lge-mediated disease
The methods and compositions described herein are based, in part, on the discovery of a polypeptide of soluble cd23 (scd23) that binds and sequesters ige. Thus, the scd23 peptides, polypeptides and derivatives described herein are useful for treating conditions or disorders involving increased ige levels such as e.g., allergy, anaphylaxis, inflammation, lymphoma, and certain cancers..
06/25/15
20150175710
 Alpha-enolase specific antibodies and  use in immune diseases patent thumbnailAlpha-enolase specific antibodies and use in immune diseases
A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against eno1. The antagonist binds eno1 and inhibits eno1 plasminogen receptor activity.
Development Center For Biotechnology
06/25/15
20150174225
 Nanoparticles for treatment of allergy patent thumbnailNanoparticles for treatment of allergy
The present invention encompasses the surprising finding that nanoparticle compositions can have beneficial effects on allergy even when prepared without a known specific allergy therapeutic. The present invention provides such nanoparticle compositions.
Allertein Therapeutics, Llc
06/11/15
20150158874
 Novel pyridopyrimidine derivatives and use thereof patent thumbnailNovel pyridopyrimidine derivatives and use thereof
The invention provides novel substituted pyridopyrimidines represented by formula i or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ oh kinase family (pi3k) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders..
Cmg Pharmaceutical Co., Ltd.
06/04/15
20150153358
 Materials and methods for diagnosing and treating shellfish allergy patent thumbnailMaterials and methods for diagnosing and treating shellfish allergy
The disclosure provides materials and methods for diagnosing, treating and preventing shellfish allergic reactions, including allergic reactions to shrimp. The technology involves one or more shellfish-specific proteins selected from the group of myosin light chain, sarcoplasmic calcium-binding protein, hemocyanin, fatty acid binding protein, and troponin c, for example from shrimp, as well as encoding polynucleotides, vectors host cells, and specific binding partners for such proteins, e.g., antibodies.
Icahn School Of Medicine At Mount Sinai
06/04/15
20150152148
 Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies patent thumbnailHypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies
The present invention refers to recombinant and molecules coding to hybrids polypeptides of different allergens from d. Pteronyssinus useful for the prevention and treatment of allergies, particularly allergies caused by mites.
Bial Industrial Farmaceutica, S.a.
06/04/15
20150152138
 Uses of kappa opioid synthetic peptide amides patent thumbnailUses of kappa opioid synthetic peptide amides
The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.
06/04/15
20150150926
 Composite with antibacterial and antipruritic functions patent thumbnailComposite with antibacterial and antipruritic functions
A composite with antibacterial and antipruritic functions includes a first substrate extracted from a plant, a second substrate and a base, and the first substrate includes a loniceraiaponica extract and an acanthopanax extract, and both loniceraiaponica extract and acanthopanax extract have a weight percentage ranging from 0.75 to 1.33, and the composite can effectively restrain the itch caused by skin pustules, folliculitis, and mosquito bites, and achieve the moisturization and antipruritic and anti-dander effects for mitigating the symptoms caused by candida albicans and staphylococcus aureus. In addition, this composite has good effects on general skin diseases such as hand eczema (ktpp), eczema, and lip herpes.
Li Tzu Pao Mei Regiman Beauty Public Ltd. Company
06/04/15
20150150925
 Wound healing composite with a function of promoting the growth of granulation tissues patent thumbnailWound healing composite with a function of promoting the growth of granulation tissues
A composite with antibacterial and antipruritic functions includes a first substrate extracted from a plant, a second substrate and a base, and the first substrate includes a loniceraiaponica extract and an acanthopanax extract, and both loniceraiaponica extract and acanthopanax extract have a weight percentage ranging from 0.75 to 1.33, and the composite can effectively restrain the itch caused by skin pustules, folliculitis, and mosquito bites, and achieve the moisturization and antipruritic and anti-dander effects for mitigating the symptoms caused by candida albicans and staphylococcus aureus. In addition, this composite has good effects on general skin diseases such as hand eczema (ktpp), eczema, and lip herpes.
Li Tzu Pao Mei Regiman Beauty Public Ltd. Company
06/04/15
20150150924
 Wound healing composite with a function of promoting the growth of granulation tissues patent thumbnailWound healing composite with a function of promoting the growth of granulation tissues
A wound healing composite with a function of promoting the growth of granulation tissues includes a substrate extracted from a plant and a base, and the substrate includes a loniceraiaponica extract, a mugwort extract, and ginkgo, and both loniceraiaponica extract and ginkgo have a weight percentage ranging from 0.28% to 3.5%. The wound healing composite can effectively promote the growth of granulation tissues, and loniceraiaponica, mugwort, ginkgo and other ingredients are extracts of natural plants, and thus the wound healing composite has a low drug resistance and does not have the side effect of drug allergy or the doubt leading to skin cancer..
Li Tzu Pao Mei Regiman Beauty Public Ltd. Company
05/28/15
20150149230

Playdate scheduling system


A social scheduling system includes member profile information. Each member profile includes information about a member and one or more of the member's associated entities.
05/28/15
20150148361

Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.. .
Janssen Pharmaceutica Nv
05/21/15
20150140140

Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care


The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—free-b-ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions associated with the skin. This composition of matter simultaneously inhibits cyclooxygenase (cox) and lipoxygenase (lox) enzymatic activity in normal, aged and damaged dermal cells and tissues.
Unigen, Inc.
05/21/15
20150140137

Combined allergy treatment and anti-drying compositions and related methods


Compositions and methods for alleviating an allergy condition while also reducing a drying effect of an allergy treatment composition or another anti-mucosal composition. In some embodiments and implementations, a composition may be provided comprising an allergy treatment composition comprising an antihistamine in a therapeutically effective amount for treating the allergy condition in the human having the allergy condition.
Xlear, Inc.
05/21/15
20150140012

Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis


The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions..
Nuvo Research Ag
05/14/15
20150133533

Compositions and methods for the treatment of cough


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for treating or preventing cough may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
05/07/15
20150126898

Fully self-contained unit dose devices for allergy skin testing


The present invention discloses a system for applying antigens or other diagnostic substances to the skin of a subject for allergy testing. The system is comprised of fully contained predetermined quantities of antigenic or other testing material contained in sealed unit doses that maintain sterility and provide for precise handling and administration.
Mystic Pharmaceuticals, Inc.
05/07/15
20150126593

Compositions and methods for the treatment of asthma and allergy


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of asthma and allergy may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
05/07/15
20150126459

Plant profilin polypeptides for use in non-specific allergy immunotherapy


The invention relates to the treatment of a hypersensitivity immune response caused by a non-profilin allergen of a profilin-containing plant material (e.g. Grass or tree pollen) by bystander suppression with a plant profilin (e.g.
Alk-abello A/s
04/30/15
20150118264

Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen


The present invention is directed to a pharmaceutical composition including (e.g. For use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh
04/30/15
20150118183

Negatively charged nucleic acid comprising complexes for immunostimulation


The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. Peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen.
Curevac Gmbh
04/30/15
20150116485

Device to shade persons from bright sunshine, dynamically from large height by matching shade pattern to presence


A device, system and method of shading person large open area from large height without obstruction to view, work and play by matching shade pattern formed by shading unit for the given sun position and the location of the person on land and building, by means of shading units moved by control from computer and by manual control and providing local cooling by directed, pulsed cold air jet. Shading unit supported by cables and at periphery shading unit on cantilever based support is used and for small areas.
04/09/15
20150098969

Alternaria peptides


Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the alternaria and/or cladosporium genus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a) a polypeptide comprising the amino acid sequence of wswkigpaiatgnt (alt28; seq id no: 101) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b) a polypeptide comprising the amino acid sequence of kyrrvvragvkvaqtar (alt34a; seq id no: 107) or a t cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of kyagvfvstgtlggg (seq id no: 112) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d) a polypeptide comprising the amino acid sequence of aevyqklkalakktygq (alt13a; seq id no: 83) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (e) a polypeptide comprising the amino acid sequence of slgfnikatnggtld (alt01a; seq id no: 60) or a t cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (f) a polypeptide comprising the amino acid sequence of sakrmkvafkldiek (alt06; seq id no: 72) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (g) a polypeptide comprising the amino acid sequence of dityvatatlpnycr (seq id no: 111) or a t cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; and (h) a polypeptide comprising the amino acid sequence of gwgvmvshrsget (alt14; seq id no: 84) or a t cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; wherein a t cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to seven amino acid modifications, each of which is independently a deletion, substitution or insertion, and each polypeptide is up to 30 amino acids in length.. .
Circassia Limited
04/09/15
20150098952

Novel therapeutic target and diagnostic marker for asthma and related conditions


Cd48, a surface-marker molecule present in eosinophils, is disclosed herein as a key molecule in allergic conditions, particularly in allergic airway inflammations like asthma, allergy and nasal polyposis. Cd48 is thus presented as a target molecule in the treatment of said conditions.
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd
03/26/15
20150087697

Compositions and methods for the treatment of muscle pain


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i; and methods for treating or preventing muscle pain, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
03/26/15
20150086594

Anti-allergic medicament


The present disclosure relates to a method for the treatment of allergic conditions. In said method the allergens to which an individual is susceptible is identified as per the allergy profile and accordingly a formulation having potentized dispersions of each of the identified allergens is administered to the individual for a predetermined period and at a predetermined potency.
03/26/15
20150086593

Allergy inhibitor compositions and kits and methods of using the same


Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed..
03/19/15
20150079173

Formulations decreasing particle exhalation


Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, sars, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier.
Pulmatrix, Inc.
03/19/15
20150079155

Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood


This invention concerns a liposome comprising lipids and at least one active ingredient, wherein at least one of the lipids is a cationic lipid; said liposome exhibiting a net positive charge at physiological conditions at which said liposome preferentially adheres to monocytes in freshly drawn blood when compared to adherence to granulocytes, t-lymphocytes, b-lymphocytes and/or nk cells in freshly drawn blood, to a lipid-based pharmaceutical composition comprising said liposomes and their use in monocytic associated prophylaxis, treatment or amelioration of a condition such as cancer, an infectious disease, an inflammatory disease, an autoimmune disease or allergy.. .
Danmarks Tekniske Universitet
03/12/15
20150074237

Method for controlling information terminal apparatus


A control method causes a computer of an information terminal apparatus to perform a process including: receiving, from a first server, first display data causing a user of the information terminal apparatus to confirm the purpose of use of recipe information and asking for the permission to collect the recipe information; accessing a second server and receiving selected recipe information and control data for a cooker for preparation based on the selected recipe information; and when it is selected to permit collecting the recipe information for a purpose of use related to health care, and it is determined that selected recipe information corresponding to the set control data has an identifier indicating that the recipe is for food related to a specific constitution, disorder, disease, or allergy, transmitting the selected recipe information with the identifier, in association with a user id of the information terminal apparatus, to the first server.. .
Panasonic Intellectual Property Corporation Of America
03/05/15
20150065450

Compound of glycosaminoglycan and its preparation method as well as application


The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (ha), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the cd44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug..
Holy Stone Healthcare Co., Ltd.
03/05/15
20150065446

Compound of glycosaminoglycan and its fabrication method as well as application


The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (ha), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the cd44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug..
Holy Stone Healthcare Co., Ltd.
02/19/15
20150050301

Contiguous overlapping peptides for treatment of house dust mites allergy


Contiguous overlapping peptides (cops) for the treatment of allergic patients by specific immunotherapy (sit) are provided from the sequence of the major allergens of house dust mites der p 1 and der p 2. Such peptides while providing all potential t cell epitopes are devoid of the three dimensional structure of the original allergen, therefore reducing their ability to bind ige.
Anergis S.a.
02/12/15
20150044244

Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases


The present invention relates to treating and preventing symptoms of an allergy, asthma, an autoimmune disease, and transplant rejection using a combination vaccine containing a vaccine facilitator comprising a na/k pump inhibitor, an antigen and a dna encoding the antigen.. .
Beijing Advanccine Biotechnology Co. Ltd.
02/12/15
20150044230

Methods related to tim 3, a th1-specific cell surface molecule, for activating antigen presenting cells


The present invention provides compositions and methods useful for promoting or reducing t-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (apc) activation.
Dana-farber Cancer Institute, Inc.
02/12/15
20150044229

Methods related to tim 3, a th1-specific cell surface molecule, for activating antigen presenting cells


The present invention provides compositions and methods useful for promoting or reducing t-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (apc) activation.
Dana-farber Cancer Institute, Inc.
02/05/15
20150037330

Histamine-releasing factor (hrf), hrf-receptor and methods of modulating inflammation


Methods of treating a food allergy, allergic reactions, hypersensitivity, inflammatory responses, inflammation are provided. In one method, histamine releasing factor (hrf)/translationally controlled tumor protein (tctp) is contacted with a compound that inhibits or reduces binding of hrf/tctp to an immunoglobulin in order to treat the food allergy, allergic reaction, hypersensitivity, inflammatory response, or inflammation.
La Jolla Institute For Allergy And Immunology
01/29/15
20150031706

Novel compound useful for the treatment of degenerative and inflammatory diseases


A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..
01/29/15
20150026892

Humidity and allergy control device


A temporary artificial environment for maintaining an increased level of humidity is created over a sleeping person by suspending a perforated netting or perforated net-type material over a supporting framework creating a restricted air volume environmental or enclosed space over said sleeping person as said person respires to retard the evaporation of moisture within the said enclosed space and thereby the unwanted drying of nasopharyngeal tissues of the sleeping person by the ambient environment, thereby increasing the healthfulness of the nasal pharyngeal membranes of the sleeping person.. .
01/22/15
20150025412

Allergy testing system, method and kit


An allergy skin test kit includes a template having puncture site indicators and a computer-readable storage medium storing allergy test information that associates the puncture site indicators of the template with template locations or test substance indicators. A method of performing an allergy skin test includes providing a template having puncture site indicators.
01/22/15
20150025034

Composition for care and hygiene of the auditory canal


The aim of the invention is to propose a composition for the care and hygiene of the auditory canal, in particular a cerumenolytic composition, which is effective for dissolving and preventing the appearance of plugs of cerumen, which is free from products irritating to the auditory canal or a source of allergy, such as preservatives or surfactants of animal origin, which is biodegradable and non-toxic for the environment, which can be used under non-sterile conditions while ensuring satisfactory preservation and stability and which does not require rinsing after use thereof. To this end, the invention concerns a composition for the care and hygiene of the auditory canal that is characterised in that it comprises a pair of surfactants consisting of an n-acyl sarcosinate sodium salt having an hlb greater than or equal to 25 and a sucrose fatty acid ester having an hlb greater than or equal to 11..
Laboratoires Gilbert
01/15/15
20150017143

Composition comprising specific lactobacillus helveticus strains and reducing food and/or respiratory allergy symptoms


A composition comprising specific lactobacillus helveticus strains is provided for reducing the symptoms of allergies originating from food, respiratory or contact allergens. Preferably the composition reduces symptoms of allergies (secondary prevention) while also able to reduce sensitization (primary prevention)..
Nestec S.a.
01/08/15
20150011802

Partially halogenated, hydroxylated fullerene and allergen adsorbent using the same


Provided are a novel fullerene derivative which can adsorb quickly and efficiently an allergen which may cause a pollen allergy without releasing the allergen again, does not contain a metal or the like which may cause a harmful effect to a human body, and is easily applicable, impregnable, or chemically bondable onto surface of various materials: and a process for producing the same. The fullerene derivative is characterized in that a halogen group and many hydroxyl groups are bonded directly to a fullerene nucleus.
Totai Co., Ltd.
12/25/14
20140378456

Benzimidazole derivatives as pi3 kinase inhibitors


This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
Glaxosmithkline Llc
12/25/14
20140377311

Method of preventing allergies


The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children.
Dbv Technologies
12/18/14
20140371445

Quinic acid derivative, process for preparation and uses thereof


The present invention relates to a quinic acid derivative, preparation process of the same and pharmaceutical uses thereof. The quinic acid derivative has a quinic acid-like structure which binds to cd28, blocks t-cell signal 2 pathway via cd28, and suppresses t-cell activation.
National Applied Research Laboratories
12/11/14
20140364607

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
12/11/14
20140363818

Egfr and par2 regulation of intestinal permeability


The present invention provides methods for diagnosing an immune-mediated disease, e.g., an autoimmune disease, an allergy or an inflammatory disease. Diagnosis is made by detecting a heterozygous or homozygous genotype of haptoglobin 2 or by detecting and quantifying pre-haptoglobin 2 mrna or protein.
12/11/14
20140363470

Pharmaceutical formulations and the use thereof for the treatment of peanut allergy


The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals, such as human mammals, suffering from peanut allergy. The present invention further relates to the use of the present compositions for the therapeutic treatment for desentizing the immune system of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment of a mammal with high predisposition to develop a certain allergy.
12/04/14
20140357695

Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions


Rna interference is provided for inhibition of spleen tyrosine kinase (syk) mrna expression, in particular, for treating patients having a syk-related inflammatory condition or at risk of developing a syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.. .
12/04/14
20140357614

Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine h4 receptor


Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as h4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.. .
12/04/14
20140356372

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor


The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen.
11/27/14
20140350052

Methods and compositions for reducing serum levels of immunoglobulin e (ige)


The present disclosure provides methods and pharmaceutical compositions for reducing the serum level of immunoglobulin ige in an animal or human subject. It has been found that reducing or inhibiting the activity of the cannabinoid receptor cb2 leads to an increase in ige in serum levels.
11/27/14
20140349311

Therapeutic agent for autoimmune diseases or allergy, and screening for the therapeutic agent


Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between sema3a and a neuropilin-1/plexin-a1 heteroreceptor. The substance includes, for example, a sema3a neutralizing antibody, a neuropilin-1 neutralizing antibody, or a soluble neuropilin-1 or derivative thereof.
11/27/14
20140348935

Treatment of food intolerance and food allergy with iga


A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an igm. When administered in a therapeutic quantity based on the subject characteristics and the type of igm, symptoms of food allergy or food intolerance in that subject are inhibited.
10/30/14
20140323480

Imidazopyridine derivatives as pi3 kinase


This invention relates to the use of imidizopyridine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of imidizopyridines in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
10/30/14
20140322257

Fusion proteins representing different ns: proposal for a vaccine against allergy to mites


The present invention refers to recombinant dna molecules codifying fused peptides from different allergens from blomia tropicalis and dermatophagoides pteronyssinus having potential usefulness in prevention and treatment of allergies caused by domestic mites. Specifically, the invention discloses fusion proteins composed by different fragments of allergens der p 1, der p 2, der p 7, der p 8, blo t 5, blo t 8, blo t 18, blo t 12 and blo t 13 with reduced serum ige reactivity in allergic and non allergic individuals.
10/23/14
20140316772

Verification of extracted data


Facts are extracted from speech and recorded in a document using codings. Each coding represents an extracted fact and includes a code and a datum.
10/23/14
20140315888

Novel heterocyclic derivatives and their uses


The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type i) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer..
10/23/14
20140314800

Beta-lactoglobulin peptides for treating cow's milk protein allergy


The present invention relates to a nutritional, preferably enteral, composition for use in the treatment of cow's milk allergy in infants allergic to cow's milk containing specific beta-lactoglobulin peptides, which are able to reduce, in particular abolish the acute symptoms of cow's milk protein allergy.. .
10/09/14
20140303089

Plant hsp70 for use in the treatment of food allergy


Object of the invention is to provide a treatment for food allergy, in particular for peanut or milk allergy. This object was met by providing a plant hsp70 or a hydrolysate thereof for use in the prophylactic or therapeutic treatment of a food allergy..


Popular terms: [SEARCH]

Allergy topics: Autoimmune, Prophylactic, Ophthalmic, Autoimmune Disorder, Immune Disorder, Dermatitis, Staurosporin, Aspergillosis, Angioedema, Allergic Rhinitis, Food Allergy, Therapeutical, Bronchopulmonary, Staurosporine, Sudden Infant Death

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Allergy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergy with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.3492

3127

2 - 1 - 71